• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Mannatech Incorporated

    11/1/24 11:44:29 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email
    SC 13G 1 v1031243sc13g.htm

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )

     

    Mannatech, Incorporated


    (Name of Issuer)

     

    Common Stock, par value $0.0001


    (Title of Class of Securities)

     

    563771 10 4


    (CUSIP Number)

     

    June 14, 2022


    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)

     

     

       
     

     

    CUSIP No. 563771 10 4

     

    1.

    NAMES OF REPORTING PERSONS


    Marlin Ray Robbins

       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)
    ¨
    (b)
    x
       
    3. SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    United States
       

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5. SOLE VOTING POWER 96,362
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 96,362
    8. SHARED DISPOSITIVE POWER 0

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    96,362
       
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.1%
       
    12. TYPE OF REPORTING PERSON

    IN

     

       
     

     

    Explanatory Note:

     

    The person filing this Schedule 13G became a beneficial owner in excess of 5% of the issued and outstanding common stock of the Issuer as a result of stock repurchases conducted by the Issuer following the most recent acquisition of common stock by the person filing.  The person filing this Schedule 13G was not aware of such repurchases or that the repurchases caused him to cross the 5% ownership threshold. The date of event on the cover page of this Schedule 13G is based on certain repurchase information made avaiable by the Issuer, but cannot be determined with certainty by the person filing.

     

    Item 1.

      (a)

    Name of Issuer:

     

    Mannatech, Incorporated

         
      (b)

    Address of Issuer's Principal Executive Offices:

     

    1410 Lakeside Parkway, Suite 200

    Flower Mound, Texas 75025

         
    Item 2.
     
      (a)

    Name of Person Filing:

     

    This Schedule 13G is filed by Marlin Ray Robbins.

         
      (b)

    Address of Principal Business Office or, if None, Residence:

     

    The address of Mr. Robbins is:

    1400 Deer Path
    Flower Mound TX 75022

         
      (c)

    Citizenship:

     

    Mr. Robbins is a citizen of the United States of America.

         
      (d)

    Title of Class of Securities:

     

    Common Stock, par value $0.0001

         
      (e)

    CUSIP No.:

     

    563771 10 4

     

       
     

     

    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ A non- U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    Item 4. Ownership.
       
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount Beneficially Owned:
       
      See response to Item 9 on the cover page.
       
    (b) Percent of Class:
       
      See response to Item 11 on the cover page.
       
    (c) Number of shares as to which such person has:
       
      (i) sole power to vote or to direct the vote See response to Item 5 on cover page.
           
      (ii) shared power to vote or to direct the vote See response to Item 6 on cover page.
           
      (iii) sole power to dispose or to direct the disposition of See response to Item 7 on cover page.
           
      (iv) shared power to dispose or to direct the disposition of See response to Item 8 on cover page.

     

       
     

     

    Item 5. Ownership of Five Percent or Less of Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not Applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not Applicable.
       
    Item 8.

    Identification and Classification of Members of the Group.

       
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group.
       
      Not Applicable.
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 1, 2024

     

    /s/ Marlin Ray Robbins

    Marlin Ray Robbins

     

     

     

     

     

     

    Get the next $MTEX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      9/10/24 5:45:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    SEC Filings

    See more
    • Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      5/13/25 5:06:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Mannatech Incorporated

      10-Q - MANNATECH INC (0001056358) (Filer)

      5/13/25 4:57:24 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Mannatech Incorporated

      DEF 14A - MANNATECH INC (0001056358) (Filer)

      4/22/25 5:01:03 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

      "The Long Run" showcases a world-record journey powered by Glycan Replenishment Therapy and unmatched determination. Global health and wellness innovator Mannatech is proud to premiere Steve Edwards: The Long Run, an 11-minute short documentary chronicling the unbelievable true story of Steve Edwards—an everyday man turned endurance icon. With over 1,000 official marathons completed in record-setting average times, Edwards' legacy is one of resilience, quiet determination and the pursuit of human potential. The film debuts globally today, May 21, and is followed by an in-depth interview with Steve Edwards himself following the documentary. It is available to watch free at events.mannatech.

      5/21/25 12:16:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Fourth Quarter 2024 Financial Results

      Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter of 2024. Quarter End Results Fourth quarter net sales for 2024 were $29.0 million, a decrease of $3.7 million, or 11.3%, as compared to $32.7 million in the fourth quarter of 2023. During the fourth quarter, the company's net sales declined 9.2% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during the fourth quarter caused a decrease of $0.7 million in net sales as compared to the fourth quarter of 2023. Gross profit as a percentage of net sales improved to 80

      3/26/25 6:00:00 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MTEX
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13G filed by Mannatech Incorporated

      SC 13G - MANNATECH INC (0001056358) (Subject)

      11/1/24 11:44:29 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      1/13/23 11:03:46 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      2/7/22 6:32:28 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

      Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

      11/26/24 4:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Mannatech Announces Retirement of Alfredo Bala and Promotion of Landen Fredrick to President and CEO

      Mannatech, Incorporated (NASDAQ: MTEX) reported that Alfredo (Al) Bala, announced his retirement as the company's CEO effective April 1, 2024. J. Stanley Fredrick, Chairman of the Board of Mannatech, Incorporated stated, "Al will continue to serve the company as an advisor focused on customer acquisition and sales growth. This transition enables Al to work more closely with our associates in the field which has always been his first love. In this new role, Al will also focus on field and leadership development, leveraging his 43 years of experience in direct sales at both the field and corporate level helping to create and develop programs dedicated to growing people and sales." Mr. Fredr

      3/13/24 7:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Toth Robert

      4/A - MANNATECH INC (0001056358) (Issuer)

      3/17/25 1:23:48 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Fredrick J Stanley was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 0.76% to 356,975 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:18 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Toth Robert was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 3% to 91,130 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Financials

    Live finance-specific insights

    See more
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Third Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to slowi

      11/12/24 4:48:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Second Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply

      8/13/24 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care